© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
ICON Public Limited Company (ICLR) stock surged +2.64%, trading at $154.57 on NASDAQ, up from the previous close of $150.59. The stock opened at $150.80, fluctuating between $148.91 and $155.00 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Feb 09, 2026 | 150.80 | 155.00 | 148.91 | 154.57 | 1.32M |
| Feb 06, 2026 | 145.23 | 153.15 | 144.51 | 150.59 | 1.74M |
| Feb 05, 2026 | 162.62 | 164.72 | 144.26 | 145.39 | 1.36M |
| Feb 04, 2026 | 167.67 | 168.99 | 162.87 | 163.11 | 1.86M |
| Feb 03, 2026 | 178.43 | 178.69 | 164.93 | 167.91 | 927.32K |
| Feb 02, 2026 | 180.25 | 180.51 | 175.07 | 178.59 | 1.11M |
| Jan 30, 2026 | 183.26 | 186.00 | 176.34 | 180.25 | 944.79K |
| Jan 29, 2026 | 185.03 | 186.27 | 180.03 | 185.89 | 555.45K |
| Jan 28, 2026 | 186.96 | 190.17 | 180.84 | 186.32 | 408.17K |
| Jan 27, 2026 | 186.93 | 191.00 | 186.93 | 187.97 | 591.55K |
| Jan 26, 2026 | 185.68 | 189.99 | 183.90 | 187.42 | 450.34K |
| Jan 23, 2026 | 186.83 | 189.72 | 184.74 | 186.70 | 510.08K |
| Jan 22, 2026 | 187.95 | 190.21 | 185.38 | 186.74 | 542.52K |
| Jan 21, 2026 | 176.55 | 185.44 | 175.18 | 184.87 | 1.19M |
| Jan 20, 2026 | 178.43 | 179.47 | 173.42 | 176.57 | 750.35K |
| Jan 16, 2026 | 181.91 | 188.00 | 181.44 | 182.61 | 1.33M |
| Jan 15, 2026 | 184.01 | 184.62 | 180.00 | 182.56 | 647.02K |
| Jan 14, 2026 | 184.17 | 185.99 | 183.22 | 184.77 | 785.06K |
| Jan 13, 2026 | 182.14 | 185.23 | 180.20 | 183.29 | 865K |
| Jan 12, 2026 | 182.98 | 183.02 | 177.47 | 180.15 | 886.99K |
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.
| Employees | 41250 |
| Beta | 1.29 |
| Sales or Revenue | $8.12B |
| 5Y Sales Change% | 1.062% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Medical - Diagnostics & Research |